van Lier J E, Kan G, Autenrieth D, Hulsinga E
Cancer Treat Rep. 1978 Aug;62(8):1251-3.
A new class of potential chemotherapeutic agents consisting of steroids coupled with nucleoside bases is described. Such structures may be viewed as nucleosides in which the sugar moiety is replaced by a steroid molecule. We may therefore expect the nucleoside characteristics to give interference at the DNA level, resulting in the desired antitumor activity, whereas the steroid moiety may provide target specificity. A number of such coupling products were prepared and preliminary biologic studies are reported.
描述了一类由甾体与核苷碱基偶联而成的新型潜在化疗药物。这类结构可被视为糖部分被甾体分子取代的核苷。因此，我们可以预期核苷特性会在DNA水平产生干扰，从而产生所需的抗肿瘤活性，而甾体部分可能提供靶向特异性。制备了许多此类偶联产物，并报告了初步的生物学研究结果。
